Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRII-753
- Development stage
- Unknown
- Lead developer
- Brii Biosciences
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
BRII-753 is an investigational long-acting nucleoside reverse transcriptase translocation inhibitor (NRTTI) being developed by Brii Biosciences for the treatment and prevention of HIV-1 infection. As a prodrug of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA, also known as islatravir), BRII-753 is designed as a subcutaneous injectable formulation with the potential for extended dosing intervals, including once-monthly, once-quarterly, or twice-yearly administration. The drug functions by inhibiting the HIV reverse transcriptase enzyme, specifically through a translocation inhibition mechanism that prevents the addition of subsequent nucleotides to the viral DNA chain. While it has completed Phase 1 clinical studies, Brii Biosciences announced in 2024 that it is seeking partnership opportunities for the asset to focus on its hepatitis B portfolio.
- Other names
- EFdA prodrug
02
Targets
HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on BRII-753.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRII-753.